1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s

Third And Final Indication For NMDA Modulator

 
• By Mandy Jackson

Sage will end development for dalzanemdor after it failed in a Phase II Huntington’s disease trial, leaving the company with one commercial drug and three early-stage assets.

After building up a mid-stage R&D pipeline, all four of Sage's planned 2024 readouts were negative. (Shutterstock)

Sage Therapeutics started 2024 with two drug candidates in Phase II clinical trials across four indications and ended the year with negative readouts for all of those studies, including the Phase II DIMENSION trial of dalzanemdor (SAGE-718) as a treatment for cognitive impairment associated with Huntington’s disease. Based on that readout, Sage said on 20 November that it will discontinue development of dalzanemdor in all indications.

Key Takeaways
  • Sage’s dalzanemdor failed in its last Phase II clinical trial, testing it in cognitive impairment associated with Huntington’s disease, so the company ended development of the drug.

Dalzanemdor did not achieve statistical significance versus placebo on the primary endpoint of change from baseline on the Symbol Digit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.